For Immediate Release
September 22, 2017
SAN DIEGO, CA – WBB Securities, LLC is pleased to announce that the WBB Asset Management Long/Short Life Science Strategy (LSLSS) was the recipient of Hedgeweek USA’s 2017 Award for Best Event Driven Strategy last night in New York City. Previous winners include Third Point, LLC and Bienville Capital Management. On hand to accept the award were WBB AM Portfolio Managers Steve Brozak and John Nolan. The Hedgeweek awards are based on a peer review system whereby its readers – including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, prime brokers, custodians and advisers – are invited to elect a ‘best in class’ managers in a series of categories.
The WBB AM LSLSS strategy, launched in February 2017, focuses on early-stage therapeutic and diagnostic companies within the biotechnology and pharmaceutical sectors and takes positions in select companies as they approach key events in the regulatory pathway such as clinical data readouts and drug approvals. Year-to-date, the strategy’s best performing holding has been Esperion Therapeutics, Inc., which has seen its share price more than triple since February after announcing FDA confirmation regarding the regulatory pathway for its lead drug candidate, bempedoic acid, for LDL cholesterol lowering.
The strategy is currently open for investment. Investors who would like more information should consult the WBB AM website (www.wbbam.com) for additional details.
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.
WBB Asset Management is the investment management arm of WBB Securities, a Registered Investment Advisor. WBB Asset Management leverages the proprietary research and analytics developed at the firm to identify and invest in emerging life science companies with potentially disruptive technologies. Investors in the firm’s strategies benefit from the knowledge and expertise gained over decades of diligence within the biotech sector. The asset management division offers a series of strategies in the life sciences for potential institutional investors.
The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $4 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain. For more information, please visit www.wbbsec.com.